Top

European Journal of Clinical Microbiology & Infectious Diseases

Published in:

01-10-2017 | Editorial

Pitfalls of defining combination therapy for carbapenem-resistant Enterobacteriaceae in observational studies

Authors: D. R. Giacobbe, A. E. Maraolo, C. Viscoli

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 10/2017

Excerpt

Carbapenem-resistant Enterobacteriaceae (CRE) are now endemic in several countries [1]. Infections caused by these organisms are associated with high mortality, with the frequently multidrug-resistant phenotype of CRE being deemed as one of the major culprits [2, 3]. Indeed, clinicians have usually little choice but to use antibiotics with reduced activity; sometimes they do not have any active choice at all. Many clinicians, including ourselves, have therefore started to administer combinations of antimicrobials, mainly with the aim of taking advantage of possible additive or synergistic effects [2]. …

Munoz-Price LS, Poirel L, Bonomo RA et al (2013) Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 13:785–796CrossRefPubMedPubMedCentral

Tumbarello M, Trecarichi EM, De Rosa FG et al (2015) Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentric study. J Antimicrob Chemother 70:2133–2143CrossRefPubMed

Trecarichi EM, Tumbarello M (2017) Therapeutic options for carbapenem-resistant Enterobacteriaceae infections. Virulence [Epub ahead of print]. doi:10.1080/21505594.2017.1292196

Papadimitriou-Olivgeris M, Fligou F, Bartzavali C et al (2017) Carbapenemase-producing Klebsiella pneumoniae bloodstream infection in critically ill patients: risk factors and predictors of mortality. Eur J Clin Microbiol Infect Dis. doi:10.1007/s10096-017-2899-6

Paul M, Carmeli Y, Durante-Mangoni E et al (2014) Combination therapy for carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother 69:2305–2309CrossRefPubMed

Zusman O, Altunin S, Koppel F et al (2017) Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis. J Antimicrob Chemother 72:29–39CrossRefPubMed

Daikos GL, Tsaousi S, Tzouvelekis LS et al (2014) Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 58:2322–2328CrossRefPubMedPubMedCentral

Zusman O, Avni T, Leibovici L, Adler A et al (2013) Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems. Antimicrob Agents Chemother 57:5104–5111CrossRefPubMedPubMedCentral

Souli M, Karaiskos I, Masgala A et al (2017) Double-carbapenem combination as salvage therapy for untreatable infections by KPC- 2-producing Klebsiella pneumoniae. Eur J Clin Microbiol Infect Dis [Epub ahead of print]. doi:10.1007/s10096-017-2936-5

10.

Oliva A, Scorzolini L, Castaldi D et al (2017) Double-carbapenem regimen, alone or in combination with colistin, in the treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae (CR-Kp). J Inf Secur 74:103–106

11.

Garonzik SM, Li J, Thamlikitkul V, Paterson DL et al (2011) Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. 168 Antimicrob Agents Chemother 55:3284–3294

12.

Del Bono V, Giacobbe DR, Marchese A et al (2017) Meropenem for treating KPC-producing Klebsiella pneumoniae bloodstream infections: should we get to the PK/PD root of the paradox? Virulence 8:66–73CrossRefPubMed

13.

Pea F, Della Siega P, Cojutti P et al (2016) Might real-time pharmacokinetic/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing Klebsiella pneumoniae? Int J Antimicrob Agents 49(2):255–258CrossRefPubMed

14.

Sorlí L, Luque S, Segura C et al (2017) Impact of colistin plasma levels on the clinical outcome of patients with infections caused by extremely drug-resistant Pseudomonas aeruginosa. BMC Infect Dis 17:11CrossRefPubMedPubMedCentral

Title: Pitfalls of defining combination therapy for carbapenem-resistant Enterobacteriaceae in observational studies
Authors: D. R. Giacobbe
A. E. Maraolo
C. Viscoli
Publication date: 01-10-2017
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Clinical Microbiology & Infectious Diseases / Issue 10/2017
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-017-3010-z

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Pitfalls of defining combination therapy for carbapenem-resistant Enterobacteriaceae in observational studies

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 10/2017

An outbreak of Clostridium difficile PCR ribotype 027 in Spain: risk factors for recurrence and a novel treatment strategy

Prevalence of hereditary hemorrhagic telangiectasia in patients operated for cerebral abscess: a retrospective cohort analysis

Importance of tissue sampling, laboratory methods, and patient characteristics for detection of Pneumocystis in autopsied lungs of non-immunosuppressed individuals

Household aggregation of Staphylococcus aureus by clonal complex and methicillin resistance profiles in Starr County, Texas

A controlled comparison of the BacT/ALERT® 3D and VIRTUO™ microbial detection systems

Evaluation of Mycotube, a modified version of Lowenstein–Jensen (LJ) medium, for efficient recovery of Mycobacterium tuberculosis (MTB)

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page